Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935428 | 1.00 | BACE1 (0.47) | BACE1BACE2LMNAKDM1AHRH4 | |
| SCHEMBL1935410 | 0.89 | BACE1 (0.50) | BACE1BACE2LMNAHRH4HRH3 | |
| SCHEMBL15769076 | 0.89 | BACE1 (0.51) | BACE1BACE2LMNAHRH4HRH3 | |
| SCHEMBL19725852 | 0.85 | BACE1 (0.48) | BACE1BACE2LMNA | |
| SCHEMBL14716596 | 0.85 | BACE1 (0.61) | BACE1BACE2LMNA | |
| SCHEMBL15799730 | 0.83 | BACE1 (0.41) | BACE1BACE2LMNAKDM1AHRH4 | |
| SCHEMBL15769264 | 0.83 | BACE1 (0.41) | BACE1BACE2LMNAKDM1AHRH4 | |
| SCHEMBL7930223 | 0.83 | BACE1 (0.37) | BACE1BACE2 | |
| SCHEMBL18133256 | 0.82 | BACE1 (0.44) | BACE1BACE2LMNAHRH4HRH3 | |
| SCHEMBL19868131 | 0.77 | BACE1 (0.39) | BACE1BACE2LMNAHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | LILLY CO ELI (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3497105-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018031334-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-15 | — | — | WO | disclosed |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-8822456-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2014091352-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | PFIZER INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332943-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | BACE1 2304/4885BACE2 2680/4885LMNA 2870/4885 |
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885LMNA 1937/4885 |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885LMNA 1621/4885 |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | BACE1 2304/4885BACE2 2680/4885LMNA 2870/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885LMNA 2761/4885 |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | BACE1 1/4885BACE2 4/4885LMNA 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.